Kadans Science Partner welcomes Aviadobio to Canary Wharf life sciences centre
AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre.
The company will be joining the Kadans’ growing European ecosystem of over 450 tenants including Cytiva, Akamis Bio, GeneFirst and Sherlock Bioscience.
The Innovation Centre comprises 40,000 sq ft of wet labs, ranging from bespoke 250 sq ft to over 2,000 sq ft labs, with tenants having the option of renting a bench in a shared lab, or taking their own private lab.
According to Kadans, the the delivery of this Innovation Centre has enabled the rapid growth of the life sciences hub at Canary Wharf, providing opportunities for early-stage life science companies to collaborate and innovate.
AviadoBio joins a host of life sciences and healthcare organisations already based at Canary Wharf, including government-owned genomic health pioneer, Genomics England, Barts Health NHS Trust, Medicines and Healthcare products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation.
In tandem with the growth of the life sciences community at Canary Wharf, Kadans and Canary Wharf Group are progressing their joint venture to develop an 823,000 sq ft GIA commercial health and life sciences building, the largest in Europe, on the 3.3-hectare North Quay site, which is expected to be complete in 2027.
Lisa Deschamps, CEO of AviadoBio, said: “We are very excited about our new partnership with Kadans and our laboratory and office space in the Innovation Centre at Canary Wharf. A state-of-the-art space allows us to more comfortably accommodate our growing team who is focused on developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Additionally, the accessibility to others in the life science space further supports our company's culture and focus on nurturing breakthrough discoveries.”
Claudia Tripp, commercial asset manager at Kadans Science Partner, added: “Attracting AviadoBio to the Innovation Centre so soon after its opening underscores both the level of demand for flexible, high quality wet lab facilities and high quality of the product we have delivered at 20 Water Street.”
“It is also an illustration of the strong momentum we continue to generate in creating a go-to destination for health and life sciences organisations of all sizes at Canary Wharf. This facility also allows us to further strengthen our relationship with AviadoBio as we look to provide much needed space for start-up and early-stage companies who can subsequently grow with us at Canary Wharf.”
